NRICM101

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023) You can help expand this article with text translated from the corresponding article in Chinese. (November 2023) Click [show] for important translation instructions. View a machine-translated version of the Chinese article. Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia. Consider adding a topic to this template: there are already 394 articles in the main category, and specifying|topic= will aid in categorization. Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article. You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Chinese Wikipedia article at [[:zh:清冠一號]]; see its history for attribution. You may also add the template {{Translated|zh|清冠一號}} to the talk page. For more guidance, see Wikipedia:Translation. You can help expand this article with text translated from the corresponding article in Cantonese. (November 2023) Click [show] for important translation instructions. Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article. You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Cantonese Wikipedia article at [[:zh-yue:清冠一號]]; see its history for attribution. You may also add the template {{Translated|zh-yue|清冠一號}} to the talk page. For more guidance, see Wikipedia:Translation. (Learn how and when to remove this message)

NRICM101 (Chinese: 清冠一號; Taiwan: Chingguan Yihau; Mainland: Qīng-guān Yī-hào), is a treatment for COVID-19 developed in Taiwan using Traditional Chinese Medicine (TCM), created by the National Research Institute of Chinese Medicine (NRICM), a governmental body of Taiwan.^[1] The prescription has gained legal approval in several countries, the first TCM recipe to do so for COVID-19 treatment.^[2] In its native Taiwan, the treatment is used in conjunction with vaccinations.^[3] Amongst the formulations available are RespireAid from Sun Ten (順天堂) [zh], and COVRelief from Chuang Song Zong (莊松榮) [zh].^[4][5]

The formula is provided in granule form, which is common for Chinese patent medicine.^[6]